SR-9009 (stenabolic)

Best Price Available

Overview

SR-9009, sold as stenabolic, is a synthetic agonist of the nuclear receptors REV-ERB-alpha and REV-ERB-beta. It came out of Thomas Burris and Theodore Kamenecka laboratory work at the Scripps Research Institute and was first described in a 2012 Nature paper as a tool for pharmacologically shifting the circadian clock and the metabolism it controls (PMID: 22460951). It was never a pharmaceutical company development candidate, has never entered human trials, and has no approval anywhere. Anti-doping laboratories describe it plainly as a compound that failed to reach FDA approval and whose illegal distribution raised concern (PMID: 38735208). REV-ERB proteins sit inside the core circadian clock and repress the genes that drive the daily cycle of activity and fuel use. Activating them with a drug changes the timing and level of metabolic gene expression in liver, muscle and fat. In the original mouse work this raised energy expenditure, and in diet-induced obese mice it reduced fat mass with drops in plasma cholesterol, triglycerides, free fatty acids and glucose (PMID: 22460951). A separate group showed that REV-ERB-alpha controls mitochondrial biogenesis in oxidative muscle and that pharmacological activation increased exercise capacity in mice (PMID: 23852339). There is a serious problem with the mechanism story. When researchers built mice lacking both REV-ERB-alpha and REV-ERB-beta, SR-9009 still reduced cell viability, rewired cellular metabolism and altered gene transcription in cells that had no target left to act on. The authors concluded that the effects of SR-9009 cannot be used as a stand-in for REV-ERB activity (PMID: 31127047). In other words, some of what the compound does in cells is off-target, and which of the metabolic effects are REV-ERB-dependent is unsettled. There are no human data of any kind. No pharmacokinetics, no safety study, no efficacy trial. In the mouse studies that produced the metabolic results, the compound was given by intraperitoneal injection rather than by mouth (PMID: 22460951), which matters because SR-9009 is sold as an oral liquid and as capsules. It is prohibited in sport. WADA lists Rev-erb-alpha agonists including SR9009 and SR9011 under section S4.4, metabolic modulators, and horse and camel racing authorities have developed detection methods for it (PMID: 38735208; PMID: 42530886). When 44 products marketed online as SARMs were chemically analyzed, SR9009 was one of the unapproved drugs found in products that did not list it on the label (PMID: 29183075). What is sold as stenabolic, in liquid or capsule form, is a research chemical with no pharmacopoeial standard, no established human dose and no published human exposure. Buyers are the first humans on record taking it, and there is no monitoring of what happens next.

Potential Research Fields

Contraindications

Research Disclaimer

This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.

$59.99

up to $79.99

—

1

2

capsule, liquid

Sign in to leave a review

Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with SR-9009 (stenabolic).

Tracking since Sep 7, 2026 · 2 data points

Best Price